|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Lenalidomide in solid tumors显示文摘 | Angela Segler Apostolia-Maria Tsimberidou | 2012 | Cancer Chemotherapy and Pharmacology2012，，6： | 2 |
| 2 | Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia显示文摘 | TSIMBERIDOU A M KANTARJIAN H W WEN S | 2008 | Cancer2008，113，： | 1 |
| 3 | TNF - α targeted therapeutic approaches in patients with hematologic malignancies 显示文摘 | Tsimberidou AM Giles FJ | 2002 | Expert Review of Anticancer Therapy2002，2，3： | 1 |
| 4 | PIK3CA Mutations Frequently Coexist with RAS and BRAF mutations in Patients with Advanced Cancers显示文摘 | Janku F Lee JJ Tsimberidou AM | 2011 | PLoS One2011，6，22： | 1 |
| 5 | PIK3CA mutations in patients with advanced cancers treated with PI3K/ AKT/mTOR axis inhibitors 显示文摘 | Janku F Tsimberidou AM Garrido-Laguna I | 2011 | Mol Cancer Ther2011，10，3： | 1 |
| 6 | Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia显示文摘 | Tsimberidou AM Kantarjian HM Wen Sijin | | 0，，06： | 1 |
| 7 | Clinical outcomes and prognostic factors in patients with Riehter syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation 显示文摘 | Tsimberidou AM O13rien S Khouri I | 2006 | J Clin Onco12006，24，15： | 1 |
| 8 | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors 显示文摘 | Janku F Tsimberidou AM Garrido-Laguna I | 2011 | Mol Cancer Ther2011，10，3： | 1 |
| 9 | The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes显示文摘 | Tsimberidou AM Estey E Wen S | 2008 | Cancer2008，113，7： | 1 |
| 10 | Clinical outcomes and prognostic factors in patients with Richtegs synd,~me t,~ated with chemotherapy or chemoimnmnotherapy with or without stem-cell transplantation 显示文摘 | Tsimberidou AM O'Brien S Khouri 1 | 2006 | J Clin Onco12006，24，15： | 1 |
| 11 | Immunosuppression and infectious complications in patients with stage Ⅳ indolent lymphoma treated with a fludarabine, mitoxantrone, and dexaethasone regimen显示文摘 | Tsimberidou AM Younes A Romaguera J | 2005 | Cancer2005，104，2： | 1 |
| 12 | Per- sonalized medicine in a phase I clinical trials program: the MD anderson cancer center initiative显示文摘 | TSIMBERIDOU AM ISKANDER NG HONG DS | 2012 | Clin Cancer Res2012，18，22： | 1 |
| 13 | Activity of interferon - alpha and isotretionoin in patients with advanced, refractor lymphoid malignancies 显示文摘 | TSIMBERIDOU A M GILES F ROMAGUERA J | 2004 | Cancer2004，100，4： | 1 |
| 14 | Cardiovascular toxicity profiles of vascular-disrupting agents 显示文摘 | Subbiah IM Lenihan D J Tsimberidou AM | 2011 | Oncologist2011，16，8： | 1 |
| 15 | Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage Ⅳ indolent lymphoma 显示文摘 | Tsimberidou AM Mclaughlin P Younes A | 2002 | Blood2002，100，： | 1 |
| 16 | Evaluation of the clinical relevance of body composition parameters in patients with Cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy显示文摘 | Parsons HA Tsimberidou AM Pontikos M | 2012 | Nutr Cancer2012，64，： | 1 |
| 17 | Richter syndrome:biology,incidence,and therapeutic strategies显示文摘 | Tsimberidou AM Keating MJ | 2005 | Cancer2005，103，2： | 1 |
| 18 | Clinical outcomes and prognostic faetors in patients with Richter's syndrome treated with chemotherapy or ehemoimmunotherapy with or without stem-eell transplantation 显示文摘 | Tsimberidou AM OBrien S Khouri I | 2006 | J Clin Oneo12006，24，15： | 1 |
| 19 | Richter syndrome: biology, incidence, and therapeutic strategies 显示文摘 | Tsimberidou AM Keating MJ | 2005 | Cancer2005，103，2： | 1 |
| 20 | Gemtuzumab ozo- gamicin,fludarabine, cytarabine and cyclosporine combina- tion regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia 显示文摘 | Tsimberidou A Cortes J Thomas D | 2003 | Leuk Res2003，27，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员